Neuroinflammation in Hypertension Study

• Status: Recruiting
• Trial end date: 2023-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To demonstrate that in patients with resistant hypertension oral treatment with minocycline via inhibition of central immune cell activation and inflammation results in reduced central sympathetic outflow and concomitant lowering of BP.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Royal Perth Hospital
• Treatments: Minocycline

Criteria

Inclusion Criteria:

• Aged: 45 -65 years

• Signed informed consent

• Clinical diagnosis of Resistant Hypertension

• Daytime systolic ambulatory BP >135mmHg.

Exclusion Criteria:• eGFR of <45 mL/min/1.73m2

• History of myocardial infarction (MI) or any cardiovascular event within 3 months of screening period, clinically significant AV conduction disturbances and/or arrhythmias,

• current of past history of heart failure (LVEF ≤40%)

• psychotropic agents, antidepressants and NSAIDS

• alcohol consumption of >3 standard drinks.

• known hypersensitivity or contraindication to minocycline or other tetracyclines.